期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
WJSC 6^(th) Anniversary Special Issues(2):Mesenchymal stem cells Neurotrauma and mesenchymal stem cells treatment:From experimental studies to clinical trials 被引量:12
1
作者 Ana Maria Blanco Martinez Camila de Oliveira Goulart +2 位作者 Bruna dos Santos Ramalho Júlia Teixeira Oliveira Fernanda Martins Almeida 《World Journal of Stem Cells》 SCIE CAS 2014年第2期179-194,共16页
Mesenchymal stem cell(MSC)therapy has attracted the attention of scientists and clinicians around the world.Basic and pre-clinical experimental studies have highlighted the positive effects of MSC treatment after spin... Mesenchymal stem cell(MSC)therapy has attracted the attention of scientists and clinicians around the world.Basic and pre-clinical experimental studies have highlighted the positive effects of MSC treatment after spinal cord and peripheral nerve injury.These effects are believed to be due to their ability to differentiate into other cell lineages,modulate inflammatory and immunomodulatory responses,reduce cell apoptosis,secrete several neurotrophic factors and respond to tissue injury,among others.There are many pre-clinical studies on MSC treatment for spinal cord injury(SCI)and peripheral nerve injuries.However,the same is not true for clinical trials,particularly those concerned with nerve trauma,indicating the necessity of more well-constructed studies showing the benefits that cell therapy can provide for individuals suffering the consequences of nerve lesions.As for clinical trials for SCI treatment the results obtained so far are not as beneficial as those described in experimental studies.For these reasons basic and pre-clinical studies dealing with MSC therapy should emphasize the standardization of protocols that could be translated to the clinical set with consistent and positive outcomes.This review is based on pre-clinical studies and clinical trials available in the literature from 2010 until now.At the time of writing this article there were 43 and 36 pre-clinical and 19 and 1 clinical trials on injured spinal cord and peripheral nerves,respectively. 展开更多
关键词 NEUROTRAUMA STEM cell therapy MESENCHYMAL STEM cells pre-clinical studies clinical trials
下载PDF
动物病理学在新药开发风险控制中的作用
2
作者 杨秀进 李宪堂 +4 位作者 王辉暖 师福山 周向梅 杨利峰 赵德明 《中国比较医学杂志》 CAS 2011年第10期107-109,共3页
目的进行临床前研究的主要原因在于,保证研究中新药探索实验中尤其是研发早期试验人群的安全,因为只是减少健康志愿者身上的风险无益于保证(所有)受试者的安全。内容本文从新药研发的两个阶段分别对病理学在临床前风险控制研究中的作用... 目的进行临床前研究的主要原因在于,保证研究中新药探索实验中尤其是研发早期试验人群的安全,因为只是减少健康志愿者身上的风险无益于保证(所有)受试者的安全。内容本文从新药研发的两个阶段分别对病理学在临床前风险控制研究中的作用进行了讨论。结论在非临床前新药研发阶段的风险控制中,让病理学家参与到新药研发的风险管理队伍中来,帮助研发、监控研发,是成功研发与优良的风险管理策略相衔接的关键。 展开更多
关键词 临床前研究 病理学 临床前风险控制
下载PDF
Two-photon microscopy in pre-clinical and clinical cancer research 被引量:1
3
作者 Jun LIU 《Frontiers of Optoelectronics》 CSCD 2015年第2期141-151,共11页
The applications of two-photon microscopy (TPM) on pre-clinical and clinical study of human cancer and diseases are reviewed in this paper. First, the principle of two-photon excitation (TPE) is introduced. The re... The applications of two-photon microscopy (TPM) on pre-clinical and clinical study of human cancer and diseases are reviewed in this paper. First, the principle of two-photon excitation (TPE) is introduced. The resulting advantages of TPM for imaging studies of animal models and human samples are then elaborated. Subsequently, the applications of TPM on various aspects of tumor studies, including tumor angiogenesis, invasion and metastasis, tumor microenvironment and metabolism are introduced. Furthermore, studies of TPM on clinical human skin biopsy and the development of two-photon microendoscopy are reviewed. Finally, potential future directions are discussed. 展开更多
关键词 two-photon microscopy (TPM) intravitalimaging pre-clinical tumor studies cancer early detection cancer diagnosis medical imaging
原文传递
脓毒症临床前研究最低质量标准(MQTiPSS):基于液体复苏和抗菌药物治疗终点的质量标准(全译) 被引量:9
4
作者 陈欢 张华莉 +2 位作者 王慷慨 姚咏明 肖献忠 《中华危重病急救医学》 CAS CSCD 北大核心 2019年第11期1307-1316,共10页
正如《国际脓毒症和脓毒性休克管理指南:2016》所述,初始液体复苏及使用抗菌药物是脓毒症和脓毒性休克早期治疗的关键步骤。然而,脓毒症临床前模型中不存在这样明确的指南。为解决这些不足,2017年5月在维也纳召开了脓毒症临床前建模的... 正如《国际脓毒症和脓毒性休克管理指南:2016》所述,初始液体复苏及使用抗菌药物是脓毒症和脓毒性休克早期治疗的关键步骤。然而,脓毒症临床前模型中不存在这样明确的指南。为解决这些不足,2017年5月在维也纳召开了脓毒症临床前建模的韦格斯-伯纳德会议。与会者对2003至2012年间所发表的260篇关于脓毒症模型的高被引科研论文进行了文献综述。该综述表明超过70%的实验没有使用或者报告液体复苏和(或)抗菌药物治疗。这些信息是为脓毒症临床前建模提出一系列"推荐"和"考虑"建议的基础;本文(第三部分)详细阐述了脓毒症模型中应该强调的关于液体复苏和抗菌药物治疗的"推荐"与"考虑"建议。与人类脓毒症类似,推荐在实验模型中进行液体复苏,除非它是研究液体复苏时的对照组。复苏时首选等渗晶体液。给药途径和给药时机应该根据模型的具体要求进行调整,优先考虑对血流动力学进行动态监测而不是静态监测。应该考虑使用预先确定的终点进行液体复苏并避免液体超负荷。脓毒症临床前研究显示,抗菌药物的使用存在严重的不一致。为弥补这一缺陷,推荐在临床前研究中使用抗菌药物,并且根据具体的脓毒症模型及病原体选择抗菌药物和剂量。理想情况下,抗菌药物的使用应该密切模拟临床实践,并要考虑药物的药代动力学特征、吸收、分布和清除率的变化,以及年龄、体重、并发症等宿主因素。这些"推荐"和"考虑"建议被认为是脓毒症动物模型的"最佳实践",应该得到执行。 展开更多
关键词 抗菌药物治疗 液体复苏 脓毒症临床前研究最低质量标准(MQTiPSS) 脓毒症模型 脓毒症 脓毒性休克
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部